SciSparc (SciSparc) Growth Rank : 0 (As of May. 21, 2024)

View and export this data going back to 2014. Start your Free Trial

What is SciSparc Growth Rank?

SciSparc has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

SciSparc Growth Rank Related Terms

Thank you for viewing the detailed overview of SciSparc's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

SciSparc (SciSparc) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SciSparc Ltd (OTCPK:SPRCY) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

SPRC:USA

Address

20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916

Website

https://www.scisparc.com

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority.